2009-05-01
The Interagency Oncology Task Force (IOTF), a joint initiative between the National Cancer Institute (NCI) and the U.S. Food and Drug Administration (FDA),
has announced fellowship training opportunities for PhDs, MDs, and
MD/PhDs or their equivalents in cancer-related scientific research and
research-related regulatory review.
The objective of the IOTF Joint Fellowship Program
is to train a core of scientists in cancer research and
research-related regulatory review to develop skill sets that bridge
the two distinct processes. Fellows will learn to build awareness of
regulatory requirements into the early stages of medical product
development and will devise strategies to improve planning throughout
the research and regulatory review phases. Fellows will also learn how
to bring state-of-the art knowledge and technology to bear on the
design, conduct, and review of clinical trials.
“We believe that physicians and scientists who are highly trained in
the regulatory process, and who also have an understanding of the inner
workings of NCI and FDA, will be able to facilitate and speed the
development and approval process for drugs, especially for
chemotherapy,” said Dr. Jonathan Wiest, director for training and
education with NCI’s Center for Cancer Research.
Fellowship programs are available in:
The IOTF was established to enhance and accelerate the overall
process of developing new cancer diagnostics and therapeutics and speed
their delivery to patients.
back to top
